AMGN vs CRL
By Alex · Tickerpine
Amgen Inc. vs Charles River Laboratories Inte, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | CRL |
|---|---|---|
| Price | $416.18 | $284.37 |
| Market cap | $225.15B | $13.70B |
| P/E ratio | 25.7 | — |
| ROE | 91.47% | -7.52% |
| Profit margin | 22.95% | -5.96% |
| Revenue growth | 9.50% | -2.70% |
| Dividend yield | 2.43% | — |
| Beta | 0.41 | 1.38 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs CRL in plain English
- AMGN is the bigger company — about 16.4× the market cap of CRL.
- AMGN earns a higher return on equity (91% vs -8%).
- AMGN is growing revenue faster (10% vs -3%).
- AMGN pays a dividend (2.43%) while the other effectively doesn't.
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories Inte would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.